Psoriasis: Interplay between dysbiosis and host immune system

Kapoor, Bhupinder; Gulati, Monica; Rani, Pooja; Gupta, Reena

doi:10.1016/j.autrev.2022.103169

Cited by 28 publications

(27 citation statements)

References 182 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Primarily, we observed a microbiome dysbiosis in susceptible animals, similar to what has been described previously for psoriasis as well as for other inflammatory diseases affecting epithelia in humans ( 58 ). The exact nature of this dysbiosis is difficult to disentangle, as the bacterial communities often consist of hundreds of species.…”

Section: Discussionsupporting

confidence: 86%

Crosstalk between microbiome, regulatory T cells and HCA2 orchestrates the inflammatory response in a murine psoriasis model

Schwarz

Philippsen²,

Piticchio³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

The organ-specific microbiome plays a crucial role in tissue homeostasis, among other things by inducing regulatory T cells (Treg). This applies also to the skin and in this setting short chain fatty acids (SCFA) are relevant. It was demonstrated that topical application of SCFA controls the inflammatory response in the psoriasis-like imiquimod (IMQ)-induced murine skin inflammation model. Since SCFA signal via HCA2, a G-protein coupled receptor, and HCA2 expression is reduced in human lesional psoriatic skin, we studied the effect of HCA2 in this model. HCA2 knock-out (HCA2-KO) mice reacted to IMQ with stronger inflammation, presumably due to an impaired function of Treg. Surprisingly, injection of Treg from HCA2-KO mice even enhanced the IMQ reaction, suggesting that in the absence of HCA2 Treg switch from a suppressive into a proinflammatory type. HCA2-KO mice differed in the composition of the skin microbiome from wild type mice. Co-housing reversed the exaggerated response to IMQ and prevented the alteration of Treg, implying that the microbiome dictates the outcome of the inflammatory reaction. The switch of Treg into a proinflammatory type in HCA2-KO mice could be a downstream phenomenon. This opens the opportunity to reduce the inflammatory tendency in psoriasis by altering the skin microbiome.

show abstract

Section: Discussionsupporting

confidence: 86%

Crosstalk between microbiome, regulatory T cells and HCA2 orchestrates the inflammatory response in a murine psoriasis model

Schwarz

Philippsen²,

Piticchio³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Dysfunction of the immune system is the hallmark of psoriasis [13]. It is manifested as chronic inflammation that involves over proliferation of keratinocytes.…”

Section: Discussionmentioning

confidence: 99%

Systemic Immune Inflammatory Index Is Associated with Pustular Psoriasis: A Single Center Retrospective Study

Ibrahim¹,

Guan²,

Li³

2022

JCDSA

View full text Add to dashboard Cite

Introduction: Psoriasis is a chronic multi-systemic inflammatory skin disease that presents with erythema, thickness, and scaling of the skin. Genetic and environmental factors are associated with its etiology. Recently systemic immune inflammatory index, has been proposed as a biomarker for prognosis and severity prediction. Although it has been studied in psoriasis in general, no study exists for its association with the individual types of psoriasis. This study thus aimed to determine its association with clinical characteristics of psoriasis subtypes. Materials and Methods: Data were retrospectively retrieved from the hospital electronic medical database from January 2020 to August 2022. Only patients with CBC results were included. Clinical data retrieved were: Patients' age, gender, type of psoriasis diagnosed, body mass index, duration of the disease, family history of psoriasis, history of smoking, diabetes, and hypertension records. Laboratory data retrieved were: Complete blood count (CBC), C-reactive protein, Immunoglobulin E (IgE), Total cholesterol, Triglycerides and Low-density lipoprotein cholesterol. Data were analyzed in SPSS and GraphPad prism. Results: The study enrolled 85 patients with psoriasis; 56.47% males, and 43.53% females. 7.6% had psoriasis for less than 10 years, while 42.4% had the disease for more than 10 years. Psoriasis vulgaris was the most common diagnosis, 41.2%, followed by p. pustular, 30.6% and then p. erythroderma 28.2%. Mean age ± SD of the p. vulgaris, p. pustular and p. erythroderma patients were 47.3 ± 15.3; 45.3 ± 14.6, and 57.1 ± 11.7 respectively. SII was significantly higher in p. pustular than the rest, (p < 0.0001). SII was significantly associated with hypertension p. pustular patients. C-reactive protein was significantly upregulated in both psoriasis pustular and erythroderma but not vulgaris (all p < 0.001), while leukocytosis was observed in psoriasis pustular. Conclusion: In summary, systemic immune inflammatory index (SII) was significantly higher in psoriasis pustular How to cite this paper

show abstract

“…27,28 Hinzu kommt deren Modulation durch verschiedene externe und interne Faktoren, etwa kommensale und pathogene Mikroorganismen (Mikrobiom). 29,30 Der angeborene Schenkel des Immunsystems wird beispielsweise durch Makrophagen, neutrophile Granulozyten und (plasmazytoide) dendritische Zellen repräsentiert, der adaptive durch T-Lymphozyten, vor allem Th17-Zellen. Die Kommunikation zwischen diesen Immunzellen wird durch verschiedene Zytokine, Chemokine und andere Mediatoren, 31 vermittelt, wobei insbesondere Tumor-Nekrose-Faktor (TNF)-α und Komponenten der Interleukin (IL)-23/IL-17-Achse seit einigen Jahren als wesentliche pathogeneseorientierte therapeutische Zielstrukturen etabliert sind (Abbildung 1).…”

Section: Wo Stehen Wir?unclassified

Aktuelle Entwicklungen und Perspektiven bei Psoriasis

Schön

Wilsmann‐Theis

2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

ZusammenfassungDie Erforschung kaum einer anderen Erkrankung hat so grundlegend neue Erkenntnisse über immunologischen Regulationen und gleichzeitig eine derart rasante Entwicklung innovativer Therapien hervorgebracht wie das Studium der Psoriasis. In dieser kurzen Übersichtsarbeit umreißen wir die Grundzüge der aktuellen Psoriasisforschung unter besonderer Berücksichtigung pathophysiologischer Vorgänge und der Meilensteine bei der Zulassung verschiedener Biologika und niedermolekularer Pharmaka. Nicht zuletzt durch die Psoriasisforschung verstehen wir das Zusammenspiel der Komponenten des angeborenen und des adaptiven Immunsystems immer besser. Neue Therapeutika greifen dabei an entscheidenden Punkten in regulatorische Netzwerke ein. Ausgehend vom derzeitigen Kenntnisstand skizzieren wir einige aus unserer Sicht wesentliche zukünftige Forschungsrichtungen sowie therapeutische und klinische Entwicklungen im Bereich der Psoriasis. Diese reichen von der Erforschung genetischer, epigenetischer, zellulärer und immunologischer Mechanismen über die Untersuchung spezifischer klinischer Formen der Psoriasis und individueller systemischer Auswirkungen der Krankheit sowie ihrer Behandlung bis hin zur Einbeziehung von Big Data und künstlicher Intelligenz. Ziele sind ein ganzheitliches Verständnis der Psoriasis von der molekularen bis zur organismischen und gesellschaftlichen Ebene und darauf aufbauend individualisierte Präventions‐ und Behandlungsstrategien. Trotz beeindruckender Fortschritte muss die Psoriasisforschung sowohl im kleinen als auch im großen Maßstab weiterentwickelt werden, um den Bedürfnissen von Behandlern und Patienten noch besser gerecht zu werden.

show abstract

Psoriasis: Interplay between dysbiosis and host immune system

Cited by 28 publications

References 182 publications

Crosstalk between microbiome, regulatory T cells and HCA2 orchestrates the inflammatory response in a murine psoriasis model

Crosstalk between microbiome, regulatory T cells and HCA2 orchestrates the inflammatory response in a murine psoriasis model

Systemic Immune Inflammatory Index Is Associated with Pustular Psoriasis: A Single Center Retrospective Study

Aktuelle Entwicklungen und Perspektiven bei Psoriasis

Contact Info

Product

Resources

About